Literature DB >> 15580148

Why do anti-tumor necrosis factor antibodies work in Crohn's disease?

Bruce E Sands1.   

Abstract

Anti-tumor necrosis factor (TNF) antibodies are powerful therapeutic agents for the treatment of Crohn's disease. TNF has diverse proinflammatory effects within the intestinal mucosa and is a pivotal cytokine in the inflammatory cascade. Although anti-TNF antibodies exert a variety of anti-inflammatory effects by neutralizing the cytokine, these agents vary in their efficacy. Recent data suggest that the ability to bind transmembrane TNF is a key property necessary for efficacy. Transmembrane binding of TNF effects apoptosis of T cells, thereby alleviating a fundamental defect in Crohn's disease in the regulation of T cell populations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15580148

Source DB:  PubMed          Journal:  Rev Gastroenterol Disord        ISSN: 1533-001X


  8 in total

1.  Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.

Authors:  S Guignard; L Gossec; C Salliot; A Ruyssen-Witrand; M Luc; M Duclos; M Dougados
Journal:  Ann Rheum Dis       Date:  2006-08-10       Impact factor: 19.103

Review 2.  Managing Crohn disease in children and adolescents : focus on tumor necrosis factor antagonists.

Authors:  Shehzad A Saeed; Wallace V Crandall
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

3.  AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease.

Authors:  Kailash C Bhol; Daniel E Tracey; Brenda R Lemos; Gregory D Lyng; Emma C Erlich; David M Keane; Michael S Quesenberry; Amy D Holdorf; Lisa D Schlehuber; Shawn A Clark; Barbara S Fox
Journal:  Inflamm Bowel Dis       Date:  2013-10       Impact factor: 5.325

4.  TNFA deletion alters apoptosis as well as caspase 3 and 4 expression during otitis media.

Authors:  Joerg Ebmeyer; Anke Leichtle; Michelle Hernandez; Umay Ebmeyer; Jacob Husseman; Kwang Pak; Holger Sudhoff; David Broide; Stephen I Wasserman; Allen F Ryan
Journal:  BMC Immunol       Date:  2011-01-26       Impact factor: 3.615

Review 5.  Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870).

Authors:  Lotte Dinesen; Simon Travis
Journal:  Int J Nanomedicine       Date:  2007

6.  On the genetic involvement of apoptosis-related genes in Crohn's disease as revealed by an extended association screen using 245 markers: no evidence for new predisposing factors.

Authors:  Sonja E N Wagenleiter; Peter Jagiello; Denis A Akkad; Larissa Arning; Thomas Griga; Wolfram Klein; Jörg T Epplen
Journal:  J Negat Results Biomed       Date:  2005-11-30

Review 7.  Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial.

Authors:  Amon Asgharpour; Jianfeng Cheng; Stephen J Bickston
Journal:  Clin Exp Gastroenterol       Date:  2013-08-30

Review 8.  Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel Disease.

Authors:  Marco Vincenzo Lenti; Caterina Mengoli; Marta Vernero; Nicola Aronico; Laura Conti; Federica Borrelli de Andreis; Sara Cococcia; Antonio Di Sabatino
Journal:  Front Immunol       Date:  2020-03-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.